Journal Mobile Options
Table of Contents
Vol. 229, No. 4, 2013
Issue release date: May 2013
Section title: Original Paper
Ophthalmologica 2013;229:219-226
(DOI:10.1159/000350496)

Citicoline Oral Solution in Glaucoma: Is There a Role in Slowing Disease Progression?

Ottobelli L. · Manni G.L. · Centofanti M. · Iester M. · Allevena F. · Rossetti L.
aEye Clinic, San Paolo Hospital, University of Milan, Milan, bDipartimento di Scienze Cliniche e Medicina Traslazionale, University of Rome Tor Vegata, and cFondazione G.B. Bietti per l'Oftalmologia, IRCCS, Rome, and dLaboratorio Clinico Anatomo-Funzionale per la Diagnosi e il Trattamento del Glaucoma e delle Malattie Neurooftalmologiche, Clinica Oculistica, DINOGMI, University of Genoa, Genoa, Italy

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 9/24/2012 2:00:04 PM
Accepted: 1/30/2013
Published online: 4/23/2013

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 4

ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)

For additional information: http://www.karger.com/OPH

Abstract

Purpose: To assess the effect of citicoline on visual field rates of progression in patients with progressing glaucoma. Patients and Methods: Forty-one patients with a diagnosis of progressing glaucoma received citicoline in oral solution for 2 years. Included were patients with a disease progression of at least -1 dB/year (at MD, mean deviation) for at least 3 years before entering the study despite controlled intraocular pressure (IOP). Patients were followed with 4 visual field examinations per year for 2 years. Results: At baseline, the mean rate of progression was -1.1 (±0.7) dB/year despite the fact that the IOP had been below 18 mm Hg for at least 3 years. At study inclusion, the mean IOP was 15.5 (±2.6) mm Hg and the mean MD was -9.2 (±6.7) dB in the worst eye. Starting from the first cycle of treatment with citicoline, the mean rate of progression significantly changed to -0.15 (±0.3) dB/year at the end of the study (p = 0.01). Conclusions: This study seems to indicate that supplementation with citicoline might significantly slow down glaucomatous rates of progression.


  

Author Contacts

Luca Rossetti, MD
Eye Clinic
San Paolo Hospital
Via di Rudinì 8, IT-20142 Milan (Italy)
E-Mail luca.rossetti@unimi.it

  

Article Information

Received: September 24, 2013
Accepted after revision: January 30, 2013
Published online: April 24, 2013
Number of Print Pages : 8
Number of Figures : 4, Number of Tables : 4, Number of References : 39

  

Publication Details

Ophthalmologica (The Journal of the European Society of Retina Specialists)

Vol. 229, No. 4, Year 2013 (Cover Date: May 2013)

Journal Editor: Cunha-Vaz J. (Coimbra)
ISSN: 0030-3755 (Print), eISSN: 1423-0267 (Online)

For additional information: http://www.karger.com/OPH


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 9/24/2012 2:00:04 PM
Accepted: 1/30/2013
Published online: 4/23/2013

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 4

ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)

For additional information: http://www.karger.com/OPH


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.